International Journal of Clinical Case Reports, 2025, Vol.15, No.3, 139-147 http://medscipublisher.com/index.php/ijccr 146 Cohen A.C., Roane B.M., and Leath C.A., 2020, Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy, Drugs, 80(3): 217-227. https://doi.org/10.1007/s40265-019-01249-z Dyer B., Feng C., Eskander R., Sharabi A., Mell L., McHale M., and Mayadev J., 2020, Current status of clinical trials for cervical and uterine cancer using immunotherapy combined with radiation, International Journal of Radiation Oncology, Biology, Physics., 109(2): 396-412. https://doi.org/10.1016/j.ijrobp.2020.09.016 Girma B., Makonnen E., and Shibeshi W., 2021, Characteristics of recent clinical investigations into systemic therapy against cervical cancer: systematic analysis of trial details from Clinicaltrials. gov, Journal of Obstetrics and Gynaecology, 42(5): 793-801. https://doi.org/10.1080/01443615.2021.1980507 Gopu P., Antony F., Cyriac S., Karakasis K., and Oza A., 2021, Updates on systemic therapy for cervical cancer, The Indian Journal of Medical Research, 154(2): 293-302. https://doi.org/10.4103/ijmr.IJMR_4454_20 Ji M., 2020, Research on cervical cancer and its drug treatment, E3S Web of Conferences, 185: 03041. https://doi.org/10.1051/e3sconf/202018503041 Kumar L., Harish P., Malik P., and Khurana S., 2018, Chemotherapy and targeted therapy in the management of cervical cancer, Current Problems in Cancer, 42(2): 120-128. https://doi.org/10.1016/j.currproblcancer.2018.01.016 Li Y., Sun Y., Zhang F., Yao Q., Gong L., Wang Y., and Gao W., 2024, Synergic chemoimmunotherapy of cervical cancer by combining cisplatin with thermosensitive polypeptide fused interferon alpha, Advanced Therapeutics, 7(7): 2400098. https://doi.org/10.1002/adtp.202400098 Liontos M., Kyriazoglou A., Dimitriadis I., Dimopoulos M., and Bamias A., 2019, Systemic therapy in cervical cancer: 30 years in review, Critical reviews in Oncology/Hematology, 137: 9-17. https://doi.org/10.1016/J.CRITREVONC.2019.02.009 Mauricio D., Zeybek B., Tymon-Rosario J., Harold J., and Santin A., 2021, Immunotherapy in cervical cancer, Current Oncology Reports, 23: 1-12. https://doi.org/10.1007/s11912-021-01052-8 Odiase O., Noah-Vermillion L., Simone B., and Aridgides P., 2021, The incorporation of immunotherapy and targeted therapy into chemoradiation for cervical cancer: a focused review, Frontiers in Oncology, 11: 663749. https://doi.org/10.3389/fonc.2021.663749 Pimple S., and Mishra G., 2022, Cancer cervix: epidemiology and disease burden, CytoJournal, 19: 21. https://doi.org/10.25259/cmas_03_02_2021 Porras G., Nogueda J., and Chacón A., 2018, Chemotherapy and molecular therapy in cervical cancer, Reports of Practical Oncology and Radiotherapy, 23(6): 533-539. https://doi.org/10.1016/j.rpor.2018.09.002 Roszik J., Ring K., Wani K., Lazar A., Yemelyanova A., Soliman P., Frumovitz M., and Jazaeri A., 2018, Gene expression analysis identifies novel targets for cervical cancer therapy, Frontiers in Immunology, 9: 9012. https://doi.org/10.3389/fimmu.2018.02102 Schmidt M.W., Battista M.J., Schmidt M., Garcia M., Siepmann T., Hasenburg A., and Anić K., 2022, Efficacy and safety of immunotherapy for cervical cancer-a systematic review of clinical trials, Cancers, 14(2): 441. https://doi.org/10.3390/cancers14020441 Sherer M., Kotha N., Williamson C., and Mayadev J., 2022, Advances in immunotherapy for cervical cancer: recent developments and future directions, International Journal of Gynecological Cancer, 32(3): 281-287. https://doi.org/10.1136/ijgc-2021-002492 Tiwari D., Srivastava K., Kishan D., and Shah M., 2018, Cervical cancer analysis: from burden to treatment, Asian Journal of Medical Sciences, 10(1): 38-42. https://doi.org/10.3126/AJMS.V10I1.21058 Wilson E., Eskander R., and Binder P., 2024, Recent therapeutic advances in gynecologic oncology: a review, Cancers, 16(4): 770. https://doi.org/10.3390/cancers16040770 Wu S., Jiao J., Yue X., and Wang Y., 2024, Cervical cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with England and India based on the global burden of disease study 2019, Frontiers in Public Health, 12: 1358433. https://doi.org/10.3389/fpubh.2024.1358433 Xu C., Liu W., Hu Y., Li W., and Di W., 2020, Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy, Theranostics, 10(7): 3325-3339. https://doi.org/10.7150/thno.41228 Yang X., Ren H., and Fu J., 2022, Combinations of radiotherapy with immunotherapy in cervical cancer, Journal of Cancer, 13(5): 1480-1489. https://doi.org/10.7150/jca.65074 Yao H., Yan C., He Q., Li Z., Jiao A., Xin L., and Hong L., 2022, Epidemiological trends and attributable risk burden of cervical cancer: an observational study from 1990 to 2019, International Journal of Clinical Practice, 2022(1): 3356431. https://doi.org/10.1155/2022/3356431
RkJQdWJsaXNoZXIy MjQ4ODYzNA==